Inventor · disambiguated record
Gerhard Seemann
Also filed as: SEEMAN GERHARD · SEEMANN GERHARD
19 granted patents·2 pending applications·1,280 citations·filing 1992–2008
95Inventor score
Files withBEHRINGWERKE AG8AVENTIS PHARMA GMBH5BEHRING DIAGNOSTICS GMBH3BEHRINGWERKE AKTIENGELLSCHAFT1DADE BEHRING MARBURG GMBH1
Top patents by PatentIndex Score
21 records- 0196US5591828ABispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereofBEHRINGWERKE AG·Filed 1994·Granted Jan 7, 1997·622 cites·10 claims
- 0295US5959083ATetravalent bispecific receptors, the preparation and use thereofBEHRINGWERKE AKTIENGELLSCHAFT·Filed 1994·Granted Sep 28, 1999·419 cites·9 claims
- 0390US5561119AGlycosylated prodrugs, their method of preparation and their usesHOECHST LAB·Filed 1992·Granted Oct 1, 1996·107 cites·36 claims
- 0479US7060495B2Fusion proteins for prodrug activationBEHRINGWERKE AG·Filed 1997·Granted Jun 13, 2006·30 cites·23 claims
- 0573US7662383B2Chimeric antibody against tumor associated antigens and its use in diagnosing tumorsAVENTIS PHARMA GMBH·Filed 2008·Granted Feb 16, 2010·0 cites·8 claims
- 0666US6926896B2Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereofAVENTIS PHARMA GMBH·Filed 1994·Granted Aug 9, 2005·17 cites·10 claims
- 0764US7241595B2Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugatesSANOFI AVENTIS PHARMA DEUTSCHL·Filed 2002·Granted Jul 10, 2007·1 cites·20 claims
- 0864US5907034AMonoclonal antibody against complexed and non-complexed complexing agents for removing heavy metals from aqueous solutions and for analysisBEHRING DIAGNOSTICS GMBH·Filed 1995·Granted May 25, 1999·12 cites·17 claims
- 0964US5686583ASpecific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapyBEHRINGWERKE AG·Filed 1995·Granted Nov 11, 1997·14 cites·16 claims
- 1064US2006159682A1Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereofAVENTIS PHARMA GMBH·Filed 2004·Application pending·0 cites
- 1162US6475486B1Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugatesAVENTIS PHARMA GMBH·Filed 1999·Granted Nov 5, 2002·13 cites·6 claims
- 1253US5639621AMonoclonal antibodies against tumor-associated antigensBEHRINGWERKE AG·Filed 1995·Granted Jun 17, 1997·7 cites·8 claims
- 1349US6610299B1Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugatesAVENTIS PHARMA GMBH·Filed 1994·Granted Aug 26, 2003·14 cites·16 claims
- 1449US5645817AGranulocyte-binding antibody constructs, their preparation and useBEHRINGWERKE AG·Filed 1995·Granted Jul 8, 1997·11 cites·13 claims
- 1548US5837824AEpitope which binds to monoclonal antibodyBEHRING DIAGNOSTICS GMBH·Filed 1995·Granted Nov 17, 1998·3 cites·1 claims
- 1644US5730981AMonoclonal anti-ganglioside antibody and its preparationBEHRINGWERKE AG·Filed 1994·Granted Mar 24, 1998·6 cites·8 claims
- 1743US5695758AMonoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereofBEHRINGWERKE AG·Filed 1995·Granted Dec 9, 1997·2 cites·6 claims
- 1839US5674994APolynucleotides encoding the anti-PEM antibody BW835 variable domains and expression vectorsBEHRINGWERKE AG·Filed 1995·Granted Oct 7, 1997·1 cites·8 claims
- 1937US5908790AMethods for removing heavy metals from aqueous solutions and for analysisBEHRING DIAGNOSTICS GMBH·Filed 1995·Granted Jun 1, 1999·1 cites·12 claims
- 2030US6030797AMonoclonal antibodies against tumor-associated antigens, processes for the preparation thereof and the use thereofDADE BEHRING MARBURG GMBH·Filed 1998·Granted Feb 29, 2000·0 cites·5 claims
- 2130US2003082151A1Extension of the expression of transgenic proteins by immunomodulationFiled 1998·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →